SUBSCRIBE
SUBSCRIBE

Krystle Vermes

FDA
Rhythm Receives FDA Approval for IMCIVREE in Certain Patients with Obesity
The FDA approval was based on results from the largest studies conducted to date in obesity associated with POMC, PCSK1 or LEPR deficiency.
November 30, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
MediciNova’s Ibudilast Reduces Retinal Thinning in MS Trial Subjects
MediciNova announced today that it received positive Optical Coherence Tomography (OCT) results from its SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis (MS) subjects.
November 25, 2020
 · 
3 min read
 · 
Krystle Vermes
Business
Thermo Fisher to Offer Routine COVID-19 Testing for Employees
As of late, the company has already tested almost 15,000 of its 75,000 employees in a pilot program.
November 24, 2020
 · 
2 min read
 · 
Krystle Vermes
Photo courtesy of Science Advances.
CRISPR Cas-9 System Doubles Life Expectancy in Mice with Aggressive Cancers
Scientists in Israel have used the CRISPR Cas-9 gene editing system to destroy cancerous cells in mice without damaging other cells.
November 23, 2020
 · 
3 min read
 · 
Krystle Vermes
Courtesy of Getty Images
Business
Could Eli Lilly and Precision BioSciences Make Breakthroughs for DMD?
Eli Lilly and Company and Precision BioSciences, Inc. announced today that they have entered a research collaboration and exclusive license agreement.
November 20, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Researchers Create Nasal Spray for COVID-19 That May Already Be Safe for Humans
Researchers from the University of Birmingham, UK, announced today that they have developed a nasal spray that can potentially provide protection against COVID-19. Additionally, it is formulated using materials that have already been cleared for use in humans.
November 19, 2020
 · 
2 min read
 · 
Krystle Vermes
Policy
Purdue Pharma Reaches $8.34 Billion Settlement with Justice Department
A settlement valued at $8.34 billion was reached between Purdue Pharma and the Justice Department on Tuesday, which required the drug company to plead guilty to three felonies related to its marketing and distribution of OxyContin.
November 18, 2020
 · 
3 min read
 · 
Krystle Vermes
Policy
Adamis and Alkermes Eye Adjustments Following Complete Response Letters from FDA
The two companies received Complete Response Letters from the FDA this week, along with Sanofi.
November 17, 2020
 · 
2 min read
 · 
Krystle Vermes
Pictured: Eric Dube, Travere CEO/Company Courtesy
Business
Retrophin Switches Name to Travere Therapeutics in Reflection of Evolving Pipeline
Travere Therapeutics will also begin trading under the new ticker symbol, “TVTX” on the Nasdaq Global Select Market beginning on Nov. 19.
November 16, 2020
 · 
3 min read
 · 
Krystle Vermes
Photo courtesy of Synairgen.
Drug Development
Could Synairgen’s SNG001 Be an Effective COVID-19 Treatment Option?
Synairgen announced today that its data from the SG016 trial was published in the journal The Lancet Respiratory Medicine. The trial, which included 101 hospitalized COVID-19 patients, looked at SNG001 as a potential treatment.
November 13, 2020
 · 
3 min read
 · 
Krystle Vermes
Biotech Bay
New Animal Data Shows Promise for Vaxart’s Oral COVID-19 Vaccine
Vaxart announced new data from its Hamster Challenge Study today, showing that its oral COVID-19 vaccine candidate can potentially reduce viral load and induce a significant immune response.
November 12, 2020
 · 
3 min read
 · 
Krystle Vermes
Courtesy of Repelsteeltje/Getty Images
Drug Development
Pfizer’s Positive Trial Results Hint at More Possibilities for Abrocitinib
Pfizer announced today that it has received positive top-line results from the Phase III JADE REGIMEN study, examining abrocitinib for the treatment of severe atopic dermatitis.
November 11, 2020
 · 
3 min read
 · 
Krystle Vermes
Courtesy of Merck & Co. Inc.
Drug Development
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
Merck and Eisai announced today that they have new investigational data demonstrating positive top-line results from the Phase III KEYNOTE-581/CLEAR trial (Study 307).
November 10, 2020
 · 
3 min read
 · 
Krystle Vermes
PictureDesignSwiss / Shutterstock
Policy
FDA Advisory Committee Rejects Biogen’s Alzheimer’s Treatment
With the opinions that were expressed by the advisory committee, along with the data presented, the FDA will continue onward with its review process. It is expected to determine whether to approve the aducanumab Biologics License Application by March 7, 2021.
November 9, 2020
 · 
3 min read
 · 
Krystle Vermes
The late stage trial of anti-inflammatory drug Dup
Drug Development
Assembly Biosciences Falls Short with Hepatitis B Drug in Phase 2 Study
Assembly Biosciences, Inc. provided an update on Nov. 5 of its ongoing Phase 2 extension study, Study 211, examining vebicorvir (VBR, or ABI-H0731) in patients with hepatitis B virus infection.
November 6, 2020
 · 
3 min read
 · 
Krystle Vermes
Load More